Skip header and navigation

Refine By

105 records – page 1 of 11.

A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group.

https://arctichealth.org/en/permalink/ahliterature229565
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Publication Type
Article
Date
Mar-1990
Author
A S Rebuck
S. Kesten
L P Boulet
A. Cartier
D. Cockcroft
J. Gruber
F. Laberge
E. Lee-Chuy
M. Keshmiri
G F MacDonald
Author Affiliation
Edmonton General Hospital, Canada.
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Date
Mar-1990
Language
English
Publication Type
Article
Keywords
Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects - therapeutic use
Asthma - drug therapy - physiopathology
Canada
Chronic Disease
Double-Blind Method
Drug Therapy, Combination
Drug Tolerance
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Nedocromil
Peak Expiratory Flow Rate - drug effects - physiology
Quinolones - adverse effects - therapeutic use
Randomized Controlled Trials as Topic
Time Factors
Abstract
Nedocromil sodium is a pyranoquinoline dicarboxylic acid derivative, formulated in a metered-dose inhaler. Because nedocromil sodium has in vitro and in vivo anti-inflammatory properties, it was evaluated in a group of steroid-dependent patients with asthma to observe how well it might be tolerated and for evidence of any beneficial effects. In a double-blind, group-comparative study, 127 patients received nedocromil sodium and 61 received placebo, administered as two puffs of 2 mg, four times per day, for 12 weeks. Ten patients developed adverse reactions, seven receiving active drug and three patients receiving placebo. Two patients of each group withdrew because of worsening asthma. Despite selecting patients whose asthma was stable, when they were receiving established therapeutic regimens that included steroids and bronchodilators, it was found that diary-card symptom scores, morning and evening peak expiratory flow rate values, and inhaled beta-agonist usage all demonstrated slight but significant benefit with addition of nedocromil sodium. It is concluded that the inhaled, anti-inflammatory agent, nedocromil sodium, may be added to asthma-treatment regimens with the reasonable expectation of further modest symptomatic benefit.
PubMed ID
2155958 View in PubMed
Less detail

Acute bacterial maxillary sinusitis: results of U.S. and European comparative therapy trials.

https://arctichealth.org/en/permalink/ahliterature223569
Source
Am J Med. 1992 Jun 22;92(6A):70S-73S
Publication Type
Article
Date
Jun-22-1992
Author
R W Nielsen
Author Affiliation
Ear, Nose, and Throat Center of Salt Lake City, Utah.
Source
Am J Med. 1992 Jun 22;92(6A):70S-73S
Date
Jun-22-1992
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Amoxicillin - administration & dosage - therapeutic use
Amoxicillin-Potassium Clavulanate Combination
Cephalosporins - administration & dosage - therapeutic use
Clavulanic Acids - administration & dosage - therapeutic use
Double-Blind Method
Doxycycline - administration & dosage - therapeutic use
Drug Therapy, Combination - administration & dosage - therapeutic use
Female
Finland
Humans
Iceland
Male
Maxillary Sinusitis - drug therapy - microbiology
Middle Aged
Single-Blind Method
Sweden
Treatment Outcome
United States
Abstract
Loracarbef, which is the first agent of the carbacephem class of beta-lactam antibiotics to be developed, provides good activity against a broad spectrum of bacteria. A single-blinded, randomized, parallel clinical trial in 10 centers in the United States compared the efficacy and safety of loracarbef with that of amoxicillin/clavulanate potassium in the treatment of acute bacterial maxillary sinusitis. A 7-10-day regimen of loracarbef (400 mg twice daily) was as effective as amoxicillin/clavulanate (500/125 mg three times a day) and resulted in somewhat fewer side effects. The results of a European trial in Sweden, Finland, and Iceland showed that loracarbef was clinically more effective than doxycycline in the treatment of acute bacterial maxillary sinusitis.
PubMed ID
1621749 View in PubMed
Less detail

[Agents for combined pharmacotherapy in severe trauma to the brain and ENT organs].

https://arctichealth.org/en/permalink/ahliterature199091
Source
Voen Med Zh. 1999 Dec;320(12):20-3, 96
Publication Type
Article
Date
Dec-1999
Author
Iu K Ianov
A T Grechko
L A Glaznikov
Source
Voen Med Zh. 1999 Dec;320(12):20-3, 96
Date
Dec-1999
Language
Russian
Publication Type
Article
Keywords
Acute Disease
Adaptation, Physiological - drug effects
Brain Injuries - drug therapy - physiopathology
Double-Blind Method
Drug Therapy, Combination
Ear - injuries
Humans
Military Personnel
Nose - injuries
Pharynx - injuries
Russia
Time Factors
Abstract
Early complex treatment of a critical brain traumas should be aimed not only at men's life and personality saving, but also at their performance' rehabilitation. Complicity and to some degree individual nature of a critical trauma pathogenesis depend on the associative active methods of surgery interference and conservative pharmacotherapy. The article deals with well-practiced means and methods of symptomatic pharmacotherapy at the early and later stages of the brain traumas with vestibular and hearing system injures and with theoretical and clinical base for modern "quick-action adaptogens" usage in addition to psychoneurocorrectors.
PubMed ID
10732478 View in PubMed
Less detail

Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis.

https://arctichealth.org/en/permalink/ahliterature197389
Source
Aliment Pharmacol Ther. 2000 Sep;14(9):1159-62
Publication Type
Article
Date
Sep-2000
Author
G. Järnerot
M. Ström
A. Danielsson
A. Kilander
L. Lööf
R. Hultcrantz
R. Löfberg
C. Florén
A. Nilsson
O. Broström
Author Affiliation
Division of Gastroenterology, Orebro Medical Centre Hospital, Linköping, Sweden. gunnar.jarnerot@orebroll.se
Source
Aliment Pharmacol Ther. 2000 Sep;14(9):1159-62
Date
Sep-2000
Language
English
Publication Type
Article
Keywords
Adult
Aged
Allopurinol - administration & dosage - therapeutic use
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage - therapeutic use
Antimetabolites - administration & dosage - therapeutic use
Colitis, Ulcerative - drug therapy
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Mesalamine - administration & dosage - therapeutic use
Middle Aged
Recurrence
Sweden
Abstract
To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).
199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.
Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.
It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.
PubMed ID
10971232 View in PubMed
Less detail

The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group.

https://arctichealth.org/en/permalink/ahliterature219137
Source
Ann Epidemiol. 1994 Jan;4(1):1-10
Publication Type
Article
Date
Jan-1994
Source
Ann Epidemiol. 1994 Jan;4(1):1-10
Date
Jan-1994
Language
English
Publication Type
Article
Keywords
Adjuvants, Immunologic - therapeutic use
Aged
Carotenoids - therapeutic use
Clinical Protocols
Double-Blind Method
Drug Monitoring
Drug Therapy, Combination
Finland - epidemiology
Follow-Up Studies
Humans
Incidence
Lung Neoplasms - epidemiology - mortality - prevention & control - psychology
Male
Middle Aged
Patient compliance
Population Surveillance
Primary prevention - methods
Research Design
Risk factors
Smoking - adverse effects
Vitamin E - therapeutic use
beta Carotene
Abstract
The Alpha-Tocopherol, Beta-Carotene (ATBC) Lung Cancer Prevention Study was a randomized, double-blind, placebo-controlled, 2 x 2 factorial design, primary prevention trial testing the hypothesis that alpha-tocopherol (50 mg/day) and beta-carotene (20 mg/day) supplements reduce the incidence of lung cancer and possibly other cancers. Total and disease-specific mortality and incidence of various diseases and symptoms were monitored for safety. Between 1985 and 1993, 29,133 eligible male smokers aged 50 to 69 years at entry were randomized to receive daily active supplements or placebo capsules for 5 to 8 years (median 6.1 years), accumulating 169,751 follow-up years. This report describes the study design, methods, and protocol as well as the baseline characteristics and capsule compliance of the participants. The ATBC Study is the largest lung cancer chemoprevention trial conducted to date.
Notes
Comment In: Ann Epidemiol. 1994 Jan;4(1):758205274
PubMed ID
8205268 View in PubMed
Less detail

An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.

https://arctichealth.org/en/permalink/ahliterature200447
Source
Pharmacoeconomics. 1999;15 Suppl 1:55-66
Publication Type
Article
Date
1999
Author
L. Lacey
P K Hopkinson
J. Montaner
F. Leblanc
M J Gill
Author Affiliation
Glaxo Wellcome, Greenford, Middlesex, England.
Source
Pharmacoeconomics. 1999;15 Suppl 1:55-66
Date
1999
Language
English
Publication Type
Article
Keywords
Adult
Ambulatory Care - economics
Anti-HIV Agents - economics - therapeutic use
Canada
Cost-Benefit Analysis
Double-Blind Method
Drug Costs
Drug Therapy, Combination
Female
HIV Infections - drug therapy - economics
Health Care Costs
Health Resources - economics - utilization
Hospitalization - economics
Humans
Lamivudine - economics - therapeutic use
Male
Prospective Studies
Zidovudine - economics - therapeutic use
Abstract
A prospective cost-effectiveness analysis undertaken as part of the CAESAR (Canada, Australia, Europe, South Africa) placebo-controlled clinical trial showed that the addition of lamivudine to zidovudine-containing regimens for 1 year reduced progression of HIV infection to AIDS or death, as well as significantly reducing the number of hospitalisations, outpatient visits and the requirement for medications for HIV-related illness and adverse events. Data from all 1840 patients included in the 'intent-to-treat' population of the CAESAR trial were used for the present analysis. A Canadian third-party payer perspective was adopted, and all costs were adjusted to 1997 prices.
The savings associated with reduced healthcare resource use in the CAESAR study were estimated to be 1123 Canadian dollars ($Can) per patient, over the year. These savings partly offset the cost of lamivudine. The analysis showed that the addition of lamivudine to zidovudine-containing regimens resulted in an incremental cost-effectiveness ratio of $Can 14,225 [95% confidence interval (CI): $Can4383 to $Can29,577] for progression to AIDS/death avoided and of $Can5631 (95%CI: $Can2010 to $Can12,929) for HIV-related illness avoided.
Our findings indicate that treatments that slow the progression of HIV infection to AIDS or death have the potential to facilitate healthcare savings, which partly offset the drug acquisition costs. The results also demonstrate that it is possible to undertake economic evaluations in parallel with a major clinical end-point study.
PubMed ID
10537442 View in PubMed
Less detail

Antiplatelet treatment in elderly people with transient ischaemic attacks or ischaemic strokes.

https://arctichealth.org/en/permalink/ahliterature216010
Source
BMJ. 1995 Jan 7;310(6971):25-6
Publication Type
Article
Date
Jan-7-1995
Author
J. Sivenius
P J Riekkinen
M. Laakso
Author Affiliation
Department of Neurology, University of Kuopio, University Hospital, Finland.
Source
BMJ. 1995 Jan 7;310(6971):25-6
Date
Jan-7-1995
Language
English
Publication Type
Article
Keywords
Age Factors
Aged
Aged, 80 and over
Aspirin - therapeutic use
Cerebrovascular Disorders - mortality - prevention & control
Dipyridamole - therapeutic use
Double-Blind Method
Drug Therapy, Combination
Finland - epidemiology
Humans
Ischemic Attack, Transient - drug therapy - mortality
Middle Aged
Notes
Cites: Acta Neurol Scand. 1993 Jan;87(1):1-88424306
PubMed ID
7827549 View in PubMed
Less detail

Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy.

https://arctichealth.org/en/permalink/ahliterature161582
Source
Pediatrics. 2007 Sep;120(3):e702-12
Publication Type
Article
Date
Sep-2007
Author
Neil W Johnston
Piush J Mandhane
Jennifer Dai
Joanne M Duncan
Justina M Greene
Kim Lambert
Malcolm R Sears
Author Affiliation
Firestone Institute for Respiratory Health, St Joseph's Healthcare, 50 Charlton Ave E, Hamilton, Ontario, Canada L8N 4A6. njohnsto@mcmaster.ca
Source
Pediatrics. 2007 Sep;120(3):e702-12
Date
Sep-2007
Language
English
Publication Type
Article
Keywords
Acetates - therapeutic use
Adolescent
Adrenal Cortex Hormones - therapeutic use
Adrenergic beta-Agonists - therapeutic use
Age Factors
Anti-Asthmatic Agents - therapeutic use
Asthma - drug therapy - epidemiology
Child
Child, Preschool
Common Cold - epidemiology
Disease Outbreaks - prevention & control
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Multivariate Analysis
Office visits - statistics & numerical data
Ontario - epidemiology
Questionnaires
Quinolines - therapeutic use
Schools
Seasons
Severity of Illness Index
Sex Factors
Abstract
A recurring epidemic of asthma exacerbations in children occurs annually in September in North America when school resumes after summer vacation.
Our goal was to determine whether montelukast, added to usual asthma therapy, would reduce days with worse asthma symptoms and unscheduled physician visits of children during the September epidemic.
A total of 194 asthmatic children aged 2 to 14 years, stratified according to age group (2-5, 6-9, and 10-14 years) and gender, participated in a double-blind, randomized, placebo-controlled trial of the addition of montelukast to usual asthma therapy between September 1 and October 15, 2005.
Children randomly assigned to receive montelukast experienced a 53% reduction in days with worse asthma symptoms compared with placebo (3.9% vs 8.3%) and a 78% reduction in unscheduled physician visits for asthma (4 [montelukast] vs 18 [placebo] visits). The benefit of montelukast was seen both in those using and not using regular inhaled corticosteroids and among those reporting and not reporting colds during the trial. There were differences in efficacy according to age and gender. Boys aged 2 to 5 years showed greater benefit from montelukast (0.4% vs 8.8% days with worse asthma symptoms) than did older boys, whereas among girls the treatment effect was most evident in 10- to 14-year-olds (4.6% [montelukast] vs 17.0% [placebo]), with nonsignificant effects in younger girls.
Montelukast added to usual treatment reduced the risk of worsened asthma symptoms and unscheduled physician visits during the predictable annual September asthma epidemic. Treatment-effect differences observed between age and gender groups require additional investigation.
Notes
Comment In: Pediatrics. 2008 Jun;121(6):1289; author reply 1289-9018519503
PubMed ID
17766511 View in PubMed
Less detail

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.

https://arctichealth.org/en/permalink/ahliterature163973
Source
Blood Press. 2007;16(1):13-9
Publication Type
Article
Date
2007
Author
Michael A Weber
George L Bakris
Björn Dahlöf
Bertram Pitt
Eric Velazquez
Jitendra Gupte
Martin Lefkowitz
Allen Hester
Victor Shi
Matthew Weir
Sverre Kjeldsen
Barry Massie
Shawna Nesbitt
Elizabeth Ofili
Kenneth Jamerson
Author Affiliation
SUNY Downstate Medical College, 420 Lexington Avenue, Brooklyn, NY 10170, USA. michaelwebermd@cs.com
Source
Blood Press. 2007;16(1):13-9
Date
2007
Language
English
Publication Type
Article
Keywords
Aged
Amlodipine - therapeutic use
Antihypertensive Agents - therapeutic use
Benzazepines - therapeutic use
Body mass index
Diabetes Mellitus, Type 2 - complications
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Hydrochlorothiazide - therapeutic use
Hypertension - complications - drug therapy
Male
Middle Aged
Myocardial Infarction - complications
Patient Selection
Scandinavia
Stroke - complications
United States
Abstract
ACCOMPLISH is the first trial designed to compare the effects on major fatal and non-fatal cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril plus hydrochlorothiazide and amlodipine plus benazepril in hypertensive patients at high cardiovascular risk. Enrollment for this trial is now complete and this report describes the clinical characteristics of the study cohort. Patients with hypertension and a previous history of cardiovascular events, strokes or diabetes mellitus were randomized to double-blind treatment with either of the two combination regimens. The data in this report detail the clinical history and demographic characteristics in patients immediately prior to randomization to study drugs. A total of 11,454 patients were randomized. Mean age (+/-SD) was 68.4+/-6.9 years, 60% were men, and 1360 (12%) were African American. Mean body mass index (BMI) was 31.0+/-6.3 kg/m(2). At study entry, 46% of patients had a history of acute coronary syndromes, coronary artery bypass grafts or percutaneous coronary interventions; 13% had a history of stroke. A history of diabetes mellitus was reported in 6928 (60%) of patients. Mean blood pressure at baseline (on prior hypertension therapy) was 145.4/80.0 mmHg; only 38% of patients had a BP less than 140/90 mmHg. Overall, 97% of patients had received previous antihypertensive treatment (74% on at least two drugs); 53% were on oral diabetes therapy or insulin, 68% on anti-lipid therapy and 63% on anti-platelet agents. In summary, the ACCOMPLISH trial has recruited hypertensive patients at high risk of cardiovascular morbidity and mortality. It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease.
Notes
Comment In: Blood Press. 2007;16(1):4-517453745
PubMed ID
17453747 View in PubMed
Less detail

105 records – page 1 of 11.